http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7858298-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c3c65b018ce7acd6572dcfe1fbf8e0c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70514 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 |
| filingDate | 1999-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c51979d4d8feecf56f81a6272050d612 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ee59a279df0f8fc79776f2196681e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fa84e73800fe91c95423fdb70f4514f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a768e5d04eb0623e2fc5c99ccc216faa |
| publicationDate | 2010-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7858298-B1 |
| titleOfInvention | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
| abstract | This invention provides methods for inhibiting fusion of HIV-1 to CD4 + cells which comprise contacting CD4 + cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4 + cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4 + cells which comprise contacting CD4 + cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4 + cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4 + cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4 + cells effective to prevent fusion of HIV-1 to CD4 + cells and a pharmaceutically acceptable carrier. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009326011-A1 |
| priorityDate | 1996-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 356.